523 results on '"Hudecek, Michael"'
Search Results
2. Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia
3. Cellular Therapy with Engineered T Cells, Efficacy, and Side Effects: Gene Editing/Gene Therapy
4. Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells
5. Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors
6. Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma
7. Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway
8. Correction: ROR1-targeting switchable CAR-T cells for cancer therapy
9. Optimizing CAR-T treatment: A T2EVOLVE guide to raw and starting material selection
10. Reinforcement Learning Based Resource Management for CAR T-Cell Therapies
11. CART Initiatives in Europe
12. Digital transformation of CAR-T cell therapy – challenges and potential for Industry 4.0
13. CAR T-cell therapy in multiple myeloma: mission accomplished?
14. ROR1-targeting switchable CAR-T cells for cancer therapy
15. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
16. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy
17. Dual targeting Boolean logic gate CAR-T cells for selective tumor antigen encounter exert potent antitumor efficacy in advanced adrenocortical carcinoma
18. Activating the intratumoral IFN[gamma]R-pathway in adrenocortical carcinoma potently enhances antitumor functionality of CAR-T cells by modulating immune cell adhesion and responsiveness
19. CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma
20. Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview
21. Generation of CAR-T Cells with Sleeping Beauty Transposon Gene Transfer
22. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
23. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
24. Chimäre Antigenrezeptor-T-Zellen – Die Evolution zellulärer Immuntherapie von malignen zu nicht-malignen Erkrankungen.
25. The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity.
26. Cellular Therapy with Engineered T Cells, Efficacy and Side Effects
27. What is the future of immunotherapy in multiple myeloma?
28. Trust in and Acceptance of Artificial Intelligence Applications in Medicine: Mixed Methods Study
29. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
30. Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
31. Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia
32. BATF3 programs CD8+ T cell memory
33. Inefficient CAR-proximal signaling blunts antigen sensitivity
34. CAR-T-Zell-Therapie: Biologie, Wirkungen, Nebenwirkungen, Zulassung und Kosten
35. A highly soluble Sleeping Beauty transposase improves control of gene insertion
36. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
37. Zukunft der Stammzelltransplantation und neue zelluläre Therapien
38. Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations
39. BCMA CAR-T cells in multiple myeloma–ready for take-off?
40. CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors
41. Mutation-specific CAR T cells as precision therapy for IGLV3-21R110expressing high-risk chronic lymphocytic leukemia
42. ROR-1 specific CAR-T cells with CRISPR/CAS9 mediated glucocorticoid receptor-knockout exert potent antitumor efficacy in advanced adrenocortical carcinoma
43. Learning from the microbes: exploiting the microbiome to enforce T cell immunotherapy
44. CARs and other T cell therapies for MM: The clinical experience
45. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes
46. Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
47. P836: ANTIBODY-DRUG CONJUGATES AS POTENTIAL CAR-T CELL SPECIFIC OFF-SWITCH IN MULTIPLE MYELOMA
48. CARs are organized in nanodomains in the plasma membrane of T cells that accumulate at tumor contact sites
49. Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells
50. All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.